186 related articles for article (PubMed ID: 1820471)
1. Reimbursement policies constrain the practice of oncology.
Laetz T; Silberman G
JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
[TBL] [Abstract][Full Text] [Related]
2. Off-label drug use in human immunodeficiency virus disease.
Brosgart CL; Mitchell T; Charlebois E; Coleman R; Mehalko S; Young J; Abrams DI
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):56-62. PubMed ID: 8624761
[TBL] [Abstract][Full Text] [Related]
3. Reimbursement for cancer treatment: coverage of off-label drug indications.
American Society of Clinical Oncology
J Clin Oncol; 2006 Jul; 24(19):3206-8. PubMed ID: 16717290
[TBL] [Abstract][Full Text] [Related]
4. Current issues in oncology reimbursement.
Bailes JS
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):185-9. PubMed ID: 8608051
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents: comparing off-label uses among authoritative drug compendia.
Thompson DF; Keefe CC
Hosp Formul; 1993 Jul; 28(7):641-2, 647. PubMed ID: 10127046
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: reliability of compendia methods for off-label oncology indications.
Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
[TBL] [Abstract][Full Text] [Related]
7. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
8. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
9. Reimbursement: current status and future outlook.
Bailes JS
Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
[TBL] [Abstract][Full Text] [Related]
10. Off-label use of anticancer drugs.
Levêque D
Lancet Oncol; 2008 Nov; 9(11):1102-7. PubMed ID: 19012859
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Clinical Compendia Used for Medicare Part D Coverage Determinations for Off-label Prescribing in Dermatology.
Barbieri JS; St Claire K; Mostaghimi A; Albrecht J
JAMA Dermatol; 2019 Mar; 155(3):315-320. PubMed ID: 30673082
[TBL] [Abstract][Full Text] [Related]
12. ASCO supports government report: "Off-label drugs: reimbursement policies constrain physicians in choice of cancer therapies".
Oncology (Williston Park); 1991 Oct; 5(10):29-30, 33. PubMed ID: 1838269
[No Abstract] [Full Text] [Related]
13. Value and payment for oncology in the United States.
Robinson JC
Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
[TBL] [Abstract][Full Text] [Related]
14. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
15. Impact of reimbursement and health care reform on the ambulatory oncology setting.
Xistris DM; Houlihan NG
Semin Oncol Nurs; 1994 Nov; 10(4):281-7. PubMed ID: 7855455
[TBL] [Abstract][Full Text] [Related]
16. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
Messori A; Fadda V; Trippoli S
J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
[TBL] [Abstract][Full Text] [Related]
17. Payment and coverage issues affecting medical oncology.
Bailes JS
Breast Cancer Res Treat; 1993; 25(2):119-26. PubMed ID: 8347844
[TBL] [Abstract][Full Text] [Related]
18. Use and coverage of novel cancer agents in managed care.
Bailes JS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
[TBL] [Abstract][Full Text] [Related]
19. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
20. [Public financing for off-label use of drugs].
Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
